Coronavirus

A summary of today's top stories.

Paul Sax, MD, discusses remdesivir, scientific literature in the age of COVID-19, and the pandemic's long-lasting effects on the future of health care.

A series of essays consider the privileges and ethics of an immunity-based "passport" to proceed with fewer restrictions in the age of COVID-19.

Treating severe COVID-19 patients with lopinavir-ritonavir did not have any significant effect compared to standard-care control patients.

A quick summary of the day's infectious disease headlines.

The agency provided 2 new recommendation guidelines for sponsors looking to assess potential preventive and therapeutic agents for the coronavirus.

What is the hopeful expectation of the new candidates, relative to previously developed vaccines?

Rodney E. Rohde, PhD, discusses the challenges our shortage of medical laboratory specialists creates for the COVID-19 response.

Contact tracing allows epidemiological response by not only notifying people of exposure so they can quarantine, but also understanding potential exposure dynamics that allowed for disease transmission.

A brief summary of our daily coverage.

The Rutgers laboratory is now authorized to receive and test collected, prescribed samples of either nasal or saliva samples for possible COVID-19.

Preventive medicine expert William Schaffner, MD, discusses what it will take for investigators to properly assess and manufacture a vaccine.

The opening of this new category of coronavirus testing makes antigen the third type authorized by the FDA, following polymerase chain reaction and serological tests.

Medical journal editors call for managed expectations for the numerous clinical trials that will soon release results on potential COVID-19 treatments.

The bacterial pathogen Campylobacter jejuni has developed chicken and cattle specific strains since the rise of 20th century livestock farming.

A quick video summary of today's COVID-19 headlines.

An assessment of 1300 hospitalized patients in New York shows the rheumatic drug is neither beneficial nor harmful to reducing mortality from coronavirus.

The device, which uses a sample collected from the patient’s nose with a nasal swab and saline, will allow patients to collect their own sample and return it to a Rutgers laboratory in a sealed package for testing.

Investigators have pinpointed two types of cells in the lining of the nose that they say are the most likely entry points for SARS-CoV-2.

The health system’s response could be used as a teaching model for addressing future infectious disease threats.

Moderna hopes to initiate phase 2 and late stage studies of its vaccine candidate, mRNA-1273, against COVID-19.

A quick summary of our daily COVID-19 coverage.

People who live in the same household as people who tested positive for COVID-19 had a 17% chance of becoming infected themselves, a new study found.

The hourlong test programs a CRISPR molecule to detect specific signature for SARS-CoV-2 in a series of differing test samples.

Reduced T cell count in patients with coronavirus could be as important an indicator for urgent intervention as reduced respiratory function.

A new study argues artificial intelligence will be a key tool in helping to evaluate the new barrage of new scientific research.

The 15 diagnostic guidelines weigh the currently accepted definition of coronavirus, and consider the prevalence of regional cases in at-risk patients.

Managing editor Kevin Kunzmann provides a summary of our daily COVID-19 coverage.

New data from a New York City-based hospital shows patients on blood thinners had a lower mortality risk due to COVID-19.

Findings of BMC Public Health analysis suggest cost-cutting measures may delay diagnosis and treatment.